HR NEWS

Teva’s new CEO to cut 25 pct of jobs to rescue ailing drugmaker

Teva’s new CEO to cut 25 pct of jobs to rescue ailing drugmaker

Teva Pharmaceutical Industries Ltd. announced some of the most sweeping job cuts in the drug industry, eliminating 14,000 positions globally as new Chief Executive Officer Kare Schultz seeks to stabilize a company suffering from ill-timed acquisitions and rising competition for its copycat medicines. The goal is to reduce expenses by $3 billion by the end of 2019, the company said in a statement on Thursday. The drugmaker will also close a number of research facilities and factories. The workforce could shrink further as the world’s largest manufacturer of generic medicines considers more divestments, it said. The stock jumped in New York. The moves highlight the severity of the challenges facing Schultz, a turnaround specialist who is the drugmaker’s sixth CEO in five years. He shook up the management team within days of joining last month, but now the 56-year-old Dane must move swiftly to prop up a company whose debt has ballooned to more than twice its market value.

“We are taking immediate and decisive actions to reduce our cost base across our global business and become a more efficient and profitable company,” said Schultz. The stock, which last month hit a 17-year low, climbed 6.8 percent in early U.S. trading to $16.77. Shares of Teva were suspended from trading in Israel ahead of the announcement. Earlier in the day, they fell 0.5 percent to 55.60 shekels, taking the decline for this year to 60 percent. The company is working with advisory firm Evercore Inc. to review options for outstanding debt that include shrinking a revolving credit facility and extending the repayment period for some loans, according to people familiar with the matter.

Teva may also seek to reset some debt covenants and extend bond maturities, said the people, asking not to be identified because the deliberations are private. Teva, an acquisitive company by tradition, paid $40.5 billion last year to beef up its copycat medicines business and bolster growth. The deal proved to be ill-timed when profit margins for knockoff drugs in the U.S. began rapidly shrinking. Compounding the problem is the loss of its monopoly on Copaxone, the blockbuster multiple sclerosis injection that at one point generated half of Teva’s profits.

The company, whose expenses will total $16.1 billion this year, said most of the cost reduction will take place in 2018. Teva will also record a restructuring charge of at least $700 million. Schultz plans to lay out next year’s financial guidance in February, and present a longer-term plan later in 2018. Employees won’t get annual bonuses this year as the financial results are “significantly below” its yearly projections, the drugmaker said. “These are decisions I don’t take lightly but they are necessary to secure Teva’s future,” Schultz said. “Today’s announcement is about positioning Teva for a sustainable future which we will achieve with our talented people.”

Source: FInancial Express

6 months ago

By HR Reporters


Social Share : Share      

Comments.....

Submit new comment

Most Viewed

Pearson slashes 3,000 jobs, reduces dividend in latest recovery push...

11 months ago

UPSC IFS Mains examination 2017 to be conducted from December 3, Detailed Applic...

9 months ago

637,000 new pilots required for airlines over next 20 years: Boeing...

11 months ago

All women crew flies Air India jet to Stockholm from Delhi, Jayant Sinha lauds n...

10 months ago

WhatsApp co-founder Brian Acton to leave company...

9 months ago

Gene therapy helps treat life-threatening skin disease...

7 months ago

Walmart gives workers a way to get paid earlier...

6 months ago

Wanted Admin Manager - NEXA/AUTOFIN LIMITED. Click here for more details...

7 months ago

Tata Steel Netherlands workers protest Thyssenkrupp merger...

8 months ago

Air India recruitment 2018: Job notification announced, 10th pass candidates, Gr...

6 months ago

Most Shared

Mass redundancies for Quebec cookie factory...

2 years ago

Trump this: 5 bold predictions for how he’ll impact HR...

2 years ago

InfoTycoon appoints existing President and COO Kevin George to succeed James Dav...

2 years ago

Sushant Dwivedy joins Aspiring Minds as SVP-Enterprise Client Solutions...

2 years ago

Uber introduces special reward programme...

2 years ago

Standard Chartered Bank to reduce 10% corporate & institutional banking staff...

2 years ago

National CineMedia (NCM) creates Affiliate Partnerships team, names Stacie Tursi...

2 years ago

OCC Names New CFO, Treasurer, and Chief Compliance Officer...

2 years ago

Beards at work are now a major turn-off say 61% of female office workers...

2 years ago

First female fast jet pilot of Britain hired as director at PwC...

2 years ago